Trial Profile
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 24 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Feb 2012 New trial record